ALK Positive Australia is inviting Australians with non–small cell lung cancer (NSCLC) who are using tyrosine kinase inhibitors (TKIs) to share their lived experience in a new research study. The survey is anonymous, quick to complete, and aims to improve care and support for people on TKIs.
What’s the study?
The study is led by Jenni Burgess from Macquarie University, as part of her Master of Research. It examines lived experience for Australians on TKIs—covering side effects, quality of life, other medications (including allergy conditions), and whether any side effects required active care. A secondary aim is to evaluate supportive care needs for adults prescribed TKIs.
A quick note on TKIs
Tyrosine kinase inhibitors (TKIs) are medicines that block specific pathways driving cancer growth. They can be highly effective, but side effects vary and may include fatigue, muscle aches, gastrointestinal changes, or cholesterol changes. If anything feels off, your oncology team is the best place for tailored advice. Some common examples for ALKies is Alectinib or Lorlatanib.
Why participate?
- Real‑world impact: Patient insights help improve standards of care and support services.
- Every experience counts: Smooth or bumpy, your perspective adds to the full picture.
- It’s quick and anonymous: No identifying information; many finish in under 30 minutes.
Is participation voluntary?
Yes. Participation is completely voluntary, and choices won’t affect anyone’s relationship with ALK Positive Australia.
All details are on the landing page, including participant information and consent. Click below to start:
Final thought
As a community, we are strongest when our experiences are shared. If you’re able, please lend your voice to this important work. Small actions like this can lead to meaningful improvements in care for people on TKIs across Australia.
